These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 25341929)
1. Anti-metastatics: an overview of drug candidates in current pipelines. Schaap-Nutt A; Thyssen DA; Drell DW; Entschladen F Curr Pharm Des; 2014; 20(42):6522-8. PubMed ID: 25341929 [TBL] [Abstract][Full Text] [Related]
2. Targets for anti-metastatic drug development. Stock AM; Troost G; Niggemann B; Zänker KS; Entschladen F Curr Pharm Des; 2013; 19(28):5127-34. PubMed ID: 23607665 [TBL] [Abstract][Full Text] [Related]
3. Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents. Fouani L; Menezes SV; Paulson M; Richardson DR; Kovacevic Z Pharmacol Res; 2017 Jan; 115():275-287. PubMed ID: 27940016 [TBL] [Abstract][Full Text] [Related]
10. The Therapeutic Potential of Migrastatin-Core Analogs for the Treatment of Metastatic Cancer. Giralt E; Lo Re D Molecules; 2017 Feb; 22(2):. PubMed ID: 28208778 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies and micrometastasis: what is known? What must be done? Perret GY Minerva Med; 2010 Jun; 101(3):163-78. PubMed ID: 20562804 [TBL] [Abstract][Full Text] [Related]
12. Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion. Shah ET; Upadhyaya A; Philp LK; Tang T; Skalamera D; Gunter J; Nelson CC; Williams ED; Hollier BG Clin Exp Metastasis; 2016 Apr; 33(4):385-99. PubMed ID: 26932199 [TBL] [Abstract][Full Text] [Related]
13. Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways. Sarwar MS; Zhang HJ; Tsang SW Curr Med Chem; 2018; 25(38):5057-5087. PubMed ID: 28925869 [TBL] [Abstract][Full Text] [Related]
14. Calumenin and fibulin-1 on tumor metastasis: Implications for pharmacology. Zheng P; Wang Q; Teng J; Chen J Pharmacol Res; 2015 Sep; 99():11-5. PubMed ID: 25976680 [TBL] [Abstract][Full Text] [Related]
15. A Review of the Structure-Activity Relationship of Natural and Synthetic Antimetastatic Compounds. Liew SK; Malagobadan S; Arshad NM; Nagoor NH Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31947704 [TBL] [Abstract][Full Text] [Related]
16. Metastasis awakening: the challenges of targeting minimal residual cancer. Polzer B; Klein CA Nat Med; 2013 Mar; 19(3):274-5. PubMed ID: 23467237 [No Abstract] [Full Text] [Related]
17. Src and focal adhesion kinase as therapeutic targets in cancer. Brunton VG; Frame MC Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340 [TBL] [Abstract][Full Text] [Related]
18. Companion canines: an under-utilised model to aid in translating anti-metastatics to the clinic. van der Weyden L; Starkey M; Abu-Helil B; Mutsaers AJ; Wood GA Clin Exp Metastasis; 2020 Feb; 37(1):7-12. PubMed ID: 31691156 [No Abstract] [Full Text] [Related]
19. Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs. Drell TL; Zanker KS; Entschladen F Curr Pharm Des; 2012; 18(23):3416-20. PubMed ID: 22663553 [TBL] [Abstract][Full Text] [Related]
20. Experimental and clinical effects of anticoagulants on cancer progression. Van Noorden CJ; van Sluis GL; Spek CA Thromb Res; 2010 Apr; 125 Suppl 2():S77-9. PubMed ID: 20434011 [No Abstract] [Full Text] [Related] [Next] [New Search]